Brazil's AI MedTech Shock: Pure Global on ANVISA's Sudden New Data Demands.

This week, we dive into a sudden and critical regulatory update from Brazil's ANVISA that is sending ripples through the AI medical device community. A new technical clarification has redefined the rules for software-based devices, creating unexpected and costly new hurdles for foreign manufacturers trying to enter Latin America's biggest market.

We explore the two main challenges this clarification presents: a new, strict requirement for clinical data from the Brazilian population, and complex cybersecurity documentation mandates that must be localized in Portuguese and aligned with local data laws. This episode breaks down what these changes mean on the ground and why your existing global regulatory dossier may no longer be enough for Brazil.

A German MedTech scaleup, with a cutting-edge AI diagnostic software already CE-marked, targeted Brazil for its next major expansion. They prepared their submission based on the existing RDC 751 regulation, using their robust European clinical trial data. Their submission was just put on hold by ANVISA last week. The reason? The new technical note requires clinical validation on the Brazilian population, data they do not have. Now, they face an unexpected delay of at least 12-18 months to conduct a local study, a costly setback that puts their entire LATAM strategy at risk.

Key questions from this episode:
- Is your existing clinical data package now obsolete for your ANVISA submission?
- What are the specific requirements for validating an AI algorithm on the Brazilian population?
- Does your cybersecurity risk assessment comply with Brazil's LGPD data law?
- Are you prepared to submit highly technical documents in flawless, localized Portuguese?
- How can you conduct a supplementary local clinical study without a physical presence in Brazil?
- What are the hidden costs associated with this new ANVISA clarification?
- Could a local regulatory partner help you bypass the need for a full new clinical trial?

Don't let regulatory surprises derail your entry into Latin America's largest market. Pure Global combines deep local expertise with advanced AI tools to navigate complex requirements like Brazil's new SaMD regulations. We provide end-to-end support, from regulatory strategy and local representation to compiling the technical dossier needed to succeed. Let us be your partner in streamlining global market access. Contact us at info@pureglobal.com or visit us at https://pureglobal.com/.